DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Quantifying behavioral disturbance in Alzheimer's disease patients.

Author(s): Weiner MF, Tractenberg R, Teri L, Logsdon R, Thomas RG, Gamst A, Thal LJ

Affiliation(s): Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75235-9070, USA.

Publication date & source: 2000-03, J Psychiatr Res., 34(2):163-7.

Publication type: Clinical Trial; Comparative Study ; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.

In the course of a four-month study of interventions for behavioral disturbances in Alzheimer's disease (AD) patients, the following assessment instruments were examined for validity: the clinical global impression of change (CGIC), Cohen-Mansfield agitation inventory (CMAI); CERAD behavioral rating scale for dementia (BRSD), revised memory and behavioral problems checklist (RMBPC) and the agitated behavior in dementia scale (ABID). The four specific behavioral/agitation scales had excellent cross-sectional and longitudinal correlations with each other, suggesting high validity, but changes as indicated by CGIC scores did not correlate well with change scores on the other instruments. We conclude that specific behavioral instruments are preferable to the more general CGIC for detecting and quantifying behavioral disturbances in AD patients.

Page last updated: 2007-10-18

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017